GFR-话题@MedSci

#GFR#

483篇内容 | 2553人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534440, encodeId=46931534440a2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, objectType=article, longId=169067, objectId=589e16906e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=589e16906e20, replyNumber=0, likeNumber=60, createdTime=2019-06-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=589e16906e20, moduleTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=589e16906e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534439, encodeId=e3651534439a9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响, objectType=article, longId=168977, objectId=a9471689e7c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9471689e7c2, replyNumber=0, likeNumber=53, createdTime=2019-06-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9471689e7c2, moduleTitle=OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9471689e7c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534438, encodeId=c5dd1534438bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变晚期NSCLC一线选择奥希替尼获益更多, objectType=article, longId=168880, objectId=e8c1168880cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8c1168880cd, replyNumber=0, likeNumber=56, createdTime=2019-06-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8c1168880cd, moduleTitle=EGFR突变晚期NSCLC一线选择奥希替尼获益更多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8c1168880cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534437, encodeId=64f2153443e51, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, objectType=article, longId=168762, objectId=f104168e62dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f104168e62dd, replyNumber=0, likeNumber=67, createdTime=2019-06-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f104168e62dd, moduleTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f104168e62dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534436, encodeId=43f1153443664, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, objectType=article, longId=168402, objectId=fee316840246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee316840246, replyNumber=0, likeNumber=51, createdTime=2019-06-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee316840246, moduleTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fee316840246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534435, encodeId=eb8d1534435d6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**, objectType=article, longId=168256, objectId=8f0e1682568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0e1682568c, replyNumber=0, likeNumber=55, createdTime=2019-06-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0e1682568c, moduleTitle=奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0e1682568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534434, encodeId=fb2b15344344a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168217, objectId=b3e216821e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3e216821e12, replyNumber=0, likeNumber=65, createdTime=2019-06-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3e216821e12, moduleTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3e216821e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534433, encodeId=d4db153443346, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择, objectType=article, longId=168215, objectId=efa11682150c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa11682150c, replyNumber=0, likeNumber=76, createdTime=2019-06-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa11682150c, moduleTitle=吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa11682150c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534432, encodeId=12b1153443290, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, objectType=article, longId=168149, objectId=6885168149ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6885168149ba, replyNumber=0, likeNumber=54, createdTime=2019-06-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6885168149ba, moduleTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6885168149ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534431, encodeId=476b153443154, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168100, objectId=14f816810048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f816810048, replyNumber=0, likeNumber=81, createdTime=2019-06-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f816810048, moduleTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f816810048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534430, encodeId=a5151534430a2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, objectType=article, longId=167952, objectId=6ae716e9520e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae716e9520e, replyNumber=0, likeNumber=64, createdTime=2019-06-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae716e9520e, moduleTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae716e9520e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534429, encodeId=54581534429d1, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势, objectType=article, longId=167944, objectId=04f516e94484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f516e94484, replyNumber=0, likeNumber=74, createdTime=2019-06-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f516e94484, moduleTitle=ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04f516e94484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534428, encodeId=578c1534428da, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, objectType=article, longId=167761, objectId=28c616e761c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c616e761c2, replyNumber=0, likeNumber=65, createdTime=2019-06-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c616e761c2, moduleTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c616e761c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534427, encodeId=71f0153442e7d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, objectType=article, longId=167660, objectId=579916e66023, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579916e66023, replyNumber=0, likeNumber=117, createdTime=2019-06-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579916e66023, moduleTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579916e66023)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534426, encodeId=23ae153442613, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显, objectType=article, longId=167122, objectId=8e2116e1220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2116e1220a, replyNumber=0, likeNumber=16, createdTime=2019-05-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2116e1220a, moduleTitle=张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e2116e1220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534425, encodeId=52f61534425b4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗, objectType=article, longId=166834, objectId=72d01668345b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d01668345b, replyNumber=0, likeNumber=17, createdTime=2019-05-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d01668345b, moduleTitle=从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72d01668345b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534424, encodeId=1fe115344245f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略, objectType=article, longId=166827, objectId=1cda16682e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cda16682e88, replyNumber=0, likeNumber=87, createdTime=2019-05-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cda16682e88, moduleTitle=EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cda16682e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534423, encodeId=b8541534423dd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, objectType=article, longId=166771, objectId=4a7e166e7116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7e166e7116, replyNumber=0, likeNumber=62, createdTime=2019-05-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7e166e7116, moduleTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7e166e7116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534422, encodeId=d60b1534422e9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Discov：第四代EGFR抑制剂，突破点在哪？, objectType=article, longId=166728, objectId=681b166e2820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681b166e2820, replyNumber=0, likeNumber=63, createdTime=2019-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681b166e2820, moduleTitle=Cancer Discov：第四代EGFR抑制剂，突破点在哪？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681b166e2820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534421, encodeId=68cc1534421bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2019年全球EGFR抑制剂市场走向, objectType=article, longId=166686, objectId=21b9166686fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21b9166686fa, replyNumber=0, likeNumber=55, createdTime=2019-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21b9166686fa, moduleTitle=2019年全球EGFR抑制剂市场走向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21b9166686fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

宋勇教授：如何驾驭EGFR TKI三匹宝马？

2019-06-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

OS获益-陆舜教授谈达可替尼上市对EGFR突变晚期NSCLC全程管理影响

2019-06-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变晚期NSCLC一线选择奥希替尼获益更多

2019-06-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择

2019-06-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变阳性晚期NSCLC的治疗方案选择

2019-06-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**

2019-06-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择

2019-06-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用

2019-06-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效

2019-06-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势

2019-06-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大

2019-06-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果

2019-06-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显

2019-05-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗

2019-05-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略

2019-05-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达

2019-05-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Discov：第四代EGFR抑制剂，突破点在哪？

2019-05-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2019年全球EGFR抑制剂市场走向

2019-05-25

科室
- - 订阅+
  - 更多科室
工具
服务